{"id":37595,"date":"2025-03-08T11:36:05","date_gmt":"2025-03-08T11:36:05","guid":{"rendered":"https:\/\/quickassetsmarket.com\/index.php\/2025\/03\/08\/walgreens-to-go-private-in-10b-deal-with-sycamore-how-the-pharmacy-giant-fell-from-grace\/"},"modified":"2025-03-08T11:36:05","modified_gmt":"2025-03-08T11:36:05","slug":"walgreens-to-go-private-in-10b-deal-with-sycamore-how-the-pharmacy-giant-fell-from-grace","status":"publish","type":"post","link":"https:\/\/quickassetsmarket.com\/index.php\/2025\/03\/08\/walgreens-to-go-private-in-10b-deal-with-sycamore-how-the-pharmacy-giant-fell-from-grace\/","title":{"rendered":"Walgreens to go private in $10B deal with Sycamore: how the pharmacy giant fell from grace"},"content":{"rendered":"
<\/div>\n

Walgreens Boots Alliance will be taken private by Sycamore Partners in a $10 billion deal, the companies announced Thursday, marking the end of nearly a century of public trading for the US pharmacy giant. <\/p>\n

The move comes after years of financial turbulence that saw Walgreens\u2019 market value plummet from a peak of $100 billion to just $9.3 billion.<\/p>\n

Sycamore will pay $11.45 per share, an 8% premium over Walgreens\u2019 closing price of $10.60 on Thursday. <\/p>\n

In addition, shareholders could receive up to $3 per share in cash from future monetization of Walgreens\u2019 stake in primary-care provider VillageMD. <\/p>\n

The total transaction, including debt and payouts, is valued at approximately $23.7 billion, according to investment bank Leerink Partners.<\/p>\n

Amazon, Walmart, eat into Walgreens’ share<\/h2>\n

Walgreens has struggled to keep pace with changes in the retail pharmacy landscape, losing ground to competitors such as Amazon and Walmart. <\/p>\n

While rivals diversified into insurance and prescription management, Walgreens pursued an aggressive expansion strategy, investing billions into acquiring other pharmacy chains, including European giant Alliance Boots. <\/p>\n

However, the shift away from brick-and-mortar retail left the company exposed to declining foot traffic and shrinking drug margins.<\/p>\n

The company\u2019s market capitalization has fallen by 90% since 2015, and its debt burden has swelled to nearly $30 billion. <\/p>\n

Walgreens reported a net loss of $8.6 billion for the 2024 fiscal year, nearly three times the previous year\u2019s losses. <\/p>\n

While the company recently surpassed earnings and revenue expectations in its most recent quarter, analysts say the turnaround remains a long-term challenge.<\/p>\n

“You have a business that is shrinking, and then you layer on losses and cash burn, all of that was the perfect recipe for what we are seeing today,” said Brian Tanquilut, a healthcare services research analyst at Jefferies in a Reuters report. <\/p>\n

Strategic missteps by leadership compounded woes<\/h2>\n

Walgreens has spent years exploring potential buyers for parts of its business. <\/p>\n

In 2019, private equity firm KKR reportedly offered $70 billion to take the company private, but the talks did not advance. <\/p>\n

Now, Sycamore\u2019s acquisition comes at a fraction of that valuation.<\/p>\n

The company has also suffered from strategic missteps under former CEO Stefano Pessina, its largest single shareholder. <\/p>\n

During his tenure, Walgreens\u2019 market capitalization shrank by nearly half, and its expansion strategy failed to yield long-term gains. <\/p>\n

The costly $5.2 billion investment in VillageMD, once seen as a path to healthcare diversification, has now become a financial drain and a potential divestment target for Sycamore.<\/p>\n

Meanwhile, Walgreens\u2019 main competitor, CVS, has successfully diversified its business beyond retail, acquiring health insurer Aetna for nearly $70 billion in 2018. <\/p>\n

Walgreens reportedly considered buying insurer Humana but ultimately abandoned the idea, a move analysts now see as a missed opportunity.<\/p>\n

Sycamore’s turnaround strategy<\/h2>\n

Sycamore, a private equity firm known for acquiring struggling retail brands, has a history of extracting value through cost-cutting measures, store closures, and asset sales. <\/p>\n

The firm has previously acquired brands such as Staples, Talbots, and Nine West, often restructuring their operations to improve profitability.<\/p>\n

Analysts expect Sycamore to follow a similar playbook with Walgreens, possibly selling off non-core assets like Boots, its UK-based pharmacy chain, and reducing operational costs across its retail footprint. <\/p>\n

“Going private makes sense on paper,” said Ann Hynes, an analyst with Mizuho Bank, adding that Walgreens’ operational challenges would likely be better handled without commitments to shareholders.<\/p>\n

Deal structure and potential roadblocks<\/h2>\n

The transaction includes a 35-day \u201cgo-shop\u201d period, allowing Walgreens to solicit alternative bids. <\/p>\n

However, analysts believe a competing offer is unlikely given the complexity of the deal. <\/p>\n

“Given the size and number of moving parts involved\u2014a potential split of the US business, Boots, and Health\u2014we don\u2019t expect a competing bid to emerge,” said Michael Cherny, an analyst at Leerink Partners.<\/p>\n

With Walgreens set to go private, the future of its sprawling global operations remains uncertain. <\/p>\n

While Sycamore\u2019s takeover provides an opportunity for restructuring, questions remain about whether the firm\u2019s strategy will lead to long-term growth or simply a short-term financial overhaul. <\/p>\n

Investors and industry watchers will be closely monitoring the next steps as one of America\u2019s most storied pharmacy chains transitions to a new chapter under private ownership.<\/p>\n

The post Walgreens to go private in $10B deal with Sycamore: how the pharmacy giant fell from grace<\/a> appeared first on Invezz<\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Walgreens Boots Alliance will be taken private by Sycamore Partners in a $10 billion deal, the companies announced Thursday, marking the end of nearly a century of public trading for the US pharmacy giant. The move comes after years of financial turbulence that saw Walgreens\u2019 market value plummet from a peak of $100 billion to <\/p>\n","protected":false},"author":1,"featured_media":37596,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":{"0":"post-37595","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-investing"},"_links":{"self":[{"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/posts\/37595","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/comments?post=37595"}],"version-history":[{"count":0,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/posts\/37595\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/media\/37596"}],"wp:attachment":[{"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/media?parent=37595"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/categories?post=37595"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/tags?post=37595"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}